JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00

Moderna (NASDAQ:MRNA) had its price target trimmed by JPMorgan Chase & Co. from $26.00 to $25.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an underweight rating on the stock.

A number of other analysts have also issued reports on MRNA. UBS Group decreased their target price on shares of Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Evercore ISI set a $32.00 target price on Moderna in a research note on Friday, August 1st. Leerink Partners decreased their price target on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research note on Friday, August 22nd. Finally, Barclays dropped their price objective on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a research note on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.86.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $26.74 on Thursday. Moderna has a one year low of $23.15 and a one year high of $57.69. The stock has a market cap of $10.44 billion, a PE ratio of -3.55 and a beta of 2.01. The business’s fifty day moving average price is $25.94 and its two-hundred day moving average price is $27.15.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts’ consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business’s revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter last year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Moderna will post -9.61 earnings per share for the current fiscal year.

Institutional Trading of Moderna

Several large investors have recently added to or reduced their stakes in MRNA. Bayforest Capital Ltd acquired a new position in shares of Moderna during the third quarter worth about $392,000. Oregon Public Employees Retirement Fund lifted its position in Moderna by 34.5% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 39,548 shares of the company’s stock worth $1,022,000 after acquiring an additional 10,137 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Moderna by 50.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 16,246 shares of the company’s stock worth $420,000 after acquiring an additional 5,417 shares during the period. HB Wealth Management LLC boosted its holdings in Moderna by 50.2% in the 3rd quarter. HB Wealth Management LLC now owns 10,933 shares of the company’s stock worth $282,000 after acquiring an additional 3,652 shares during the period. Finally, CX Institutional grew its position in Moderna by 589.4% in the third quarter. CX Institutional now owns 7,121 shares of the company’s stock valued at $184,000 after acquiring an additional 6,088 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.